Our various professional bodies go through the evidence, and that's how we come up with the guidelines on the use of pharmaceutical agents. Obviously, if they've been recommended, they must have benefit. Other people—the health economists—will then come to do the various cost utility and cost-effectiveness studies.
I did a similar presentation to your provincial government not that long ago. We have good data from Saskatchewan, and we know that for many of the chronic conditions we could prevent through the use of effective pharmaceutical therapy, patients have difficulty in adherence. Of course, some of it may be cost-related, but some of it's just behavioural issues.
For example, we know that 60% to 70% stop taking their cholesterol-lowering medication. We might as well not have prescribed it; it's wasted money to our system. If it hasn't done anything, or if they stopped taking it, they then represent wasted lives or wasted opportunity to our system. If we had ways, through all the various strategies, to ensure and facilitate adherence, it would certainly translate into a benefit from a medical perspective.